Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
43
AVIR Quote, Financials, Valuation and Earnings
Last price:
$4.60
Seasonality move
:
-23.12%
Day range:
$4.57 - $4.70
52-week range:
$2.46 - $4.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.84x
P/B ratio:
1.14x
Volume:
461.9K
Avg. volume:
516.1K
1-year change:
48.39%
Market cap:
$359.4M
Revenue:
--
EPS (TTM):
-$1.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AVIR
Atea Pharmaceuticals, Inc.
|
-- | -$0.49 | -- | -31.71% | $7.67 |
|
ACRS
Aclaris Therapeutics, Inc.
|
$2.1M | -$0.14 | 27.15% | -8.22% | $8.00 |
|
COYA
Coya Therapeutics, Inc.
|
$1.9M | -$0.30 | -20.12% | -19.15% | $16.07 |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
-- | -$0.07 | -- | -75% | $3.25 |
|
PMVP
PMV Pharmaceuticals, Inc.
|
-- | -$0.41 | -- | -8.56% | $7.60 |
|
TIL
Instil Bio, Inc.
|
-- | -$3.78 | -- | -107.39% | $29.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AVIR
Atea Pharmaceuticals, Inc.
|
$4.60 | $7.67 | $359.4M | -- | $0.00 | 0% | 0.84x |
|
ACRS
Aclaris Therapeutics, Inc.
|
$3.17 | $8.00 | $343.5M | -- | $0.00 | 0% | 23.30x |
|
COYA
Coya Therapeutics, Inc.
|
$4.85 | $16.07 | $101.5M | -- | $0.00 | 0% | 20.34x |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
$3.30 | $3.25 | $131.3M | 3.29x | $0.25 | 7.58% | 68.69x |
|
PMVP
PMV Pharmaceuticals, Inc.
|
$1.07 | $7.60 | $56.9M | -- | $0.00 | 0% | -- |
|
TIL
Instil Bio, Inc.
|
$8.88 | $29.00 | $60.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AVIR
Atea Pharmaceuticals, Inc.
|
0.33% | 0.572 | 0.46% | 16.32x |
|
ACRS
Aclaris Therapeutics, Inc.
|
1.83% | 2.641 | 1.09% | 3.92x |
|
COYA
Coya Therapeutics, Inc.
|
-- | -0.492 | -- | 7.67x |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
0.42% | -0.079 | 0.8% | 22.01x |
|
PMVP
PMV Pharmaceuticals, Inc.
|
0.76% | 2.154 | 1.25% | 10.50x |
|
TIL
Instil Bio, Inc.
|
41.36% | 5.678 | 70.11% | 14.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AVIR
Atea Pharmaceuticals, Inc.
|
-$104K | -$45.6M | -36.83% | -36.97% | -- | -$40.4M |
|
ACRS
Aclaris Therapeutics, Inc.
|
$850K | -$17M | -102.07% | -103.93% | -516.79% | -$11M |
|
COYA
Coya Therapeutics, Inc.
|
$3.6M | -$1.9M | -57.41% | -57.41% | -53.78% | -$1.6M |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
-$31K | -$2.4M | 27.4% | 27.49% | -225% | -$2M |
|
PMVP
PMV Pharmaceuticals, Inc.
|
-$32K | -$22.5M | -50.85% | -51.97% | -- | -$19.8M |
|
TIL
Instil Bio, Inc.
|
-$12K | -$15M | -32.04% | -50.54% | -- | -$10.6M |
Atea Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns AVIR or ACRS?
Aclaris Therapeutics, Inc. has a net margin of -- compared to Atea Pharmaceuticals, Inc.'s net margin of -442.98%. Atea Pharmaceuticals, Inc.'s return on equity of -36.97% beat Aclaris Therapeutics, Inc.'s return on equity of -103.93%.
Company Gross Margin Earnings Per Share Invested Capital AVIRAtea Pharmaceuticals, Inc.-- -$0.53 $316.8M ACRSAclaris Therapeutics, Inc.25.77% -$0.12 $122.3M -
What do Analysts Say About AVIR or ACRS?
Atea Pharmaceuticals, Inc. has a consensus price target of $7.67, signalling upside risk potential of 66.67%. On the other hand Aclaris Therapeutics, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 152.37%. Given that Aclaris Therapeutics, Inc. has higher upside potential than Atea Pharmaceuticals, Inc., analysts believe Aclaris Therapeutics, Inc. is more attractive than Atea Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVIRAtea Pharmaceuticals, Inc.2 1 0 ACRSAclaris Therapeutics, Inc.6 1 0 -
Is AVIR or ACRS More Risky?
Atea Pharmaceuticals, Inc. has a beta of 0.239, which suggesting that the stock is 76.143% less volatile than S&P 500. In comparison Aclaris Therapeutics, Inc. has a beta of 0.860, suggesting its less volatile than the S&P 500 by 13.979%.
-
Which is a Better Dividend Stock AVIR or ACRS?
Atea Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aclaris Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atea Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Aclaris Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVIR or ACRS?
Atea Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Aclaris Therapeutics, Inc. quarterly revenues of $3.3M. Atea Pharmaceuticals, Inc.'s net income of -$42M is lower than Aclaris Therapeutics, Inc.'s net income of -$14.6M. Notably, Atea Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Aclaris Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atea Pharmaceuticals, Inc. is 0.84x versus 23.30x for Aclaris Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVIRAtea Pharmaceuticals, Inc.0.84x -- -- -$42M ACRSAclaris Therapeutics, Inc.23.30x -- $3.3M -$14.6M
-
Which has Higher Returns AVIR or COYA?
Coya Therapeutics, Inc. has a net margin of -- compared to Atea Pharmaceuticals, Inc.'s net margin of -59.36%. Atea Pharmaceuticals, Inc.'s return on equity of -36.97% beat Coya Therapeutics, Inc.'s return on equity of -57.41%.
Company Gross Margin Earnings Per Share Invested Capital AVIRAtea Pharmaceuticals, Inc.-- -$0.53 $316.8M COYACoya Therapeutics, Inc.99.81% -$0.13 $27.3M -
What do Analysts Say About AVIR or COYA?
Atea Pharmaceuticals, Inc. has a consensus price target of $7.67, signalling upside risk potential of 66.67%. On the other hand Coya Therapeutics, Inc. has an analysts' consensus of $16.07 which suggests that it could grow by 231.37%. Given that Coya Therapeutics, Inc. has higher upside potential than Atea Pharmaceuticals, Inc., analysts believe Coya Therapeutics, Inc. is more attractive than Atea Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVIRAtea Pharmaceuticals, Inc.2 1 0 COYACoya Therapeutics, Inc.7 0 0 -
Is AVIR or COYA More Risky?
Atea Pharmaceuticals, Inc. has a beta of 0.239, which suggesting that the stock is 76.143% less volatile than S&P 500. In comparison Coya Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AVIR or COYA?
Atea Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Coya Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atea Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Coya Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVIR or COYA?
Atea Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Coya Therapeutics, Inc. quarterly revenues of $3.6M. Atea Pharmaceuticals, Inc.'s net income of -$42M is lower than Coya Therapeutics, Inc.'s net income of -$2.1M. Notably, Atea Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Coya Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atea Pharmaceuticals, Inc. is 0.84x versus 20.34x for Coya Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVIRAtea Pharmaceuticals, Inc.0.84x -- -- -$42M COYACoya Therapeutics, Inc.20.34x -- $3.6M -$2.1M
-
Which has Higher Returns AVIR or ORMP?
Oramed Pharmaceuticals, Inc. has a net margin of -- compared to Atea Pharmaceuticals, Inc.'s net margin of -382.1%. Atea Pharmaceuticals, Inc.'s return on equity of -36.97% beat Oramed Pharmaceuticals, Inc.'s return on equity of 27.49%.
Company Gross Margin Earnings Per Share Invested Capital AVIRAtea Pharmaceuticals, Inc.-- -$0.53 $316.8M ORMPOramed Pharmaceuticals, Inc.0.65% $1.13 $203.2M -
What do Analysts Say About AVIR or ORMP?
Atea Pharmaceuticals, Inc. has a consensus price target of $7.67, signalling upside risk potential of 66.67%. On the other hand Oramed Pharmaceuticals, Inc. has an analysts' consensus of $3.25 which suggests that it could fall by -1.52%. Given that Atea Pharmaceuticals, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Atea Pharmaceuticals, Inc. is more attractive than Oramed Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVIRAtea Pharmaceuticals, Inc.2 1 0 ORMPOramed Pharmaceuticals, Inc.0 0 0 -
Is AVIR or ORMP More Risky?
Atea Pharmaceuticals, Inc. has a beta of 0.239, which suggesting that the stock is 76.143% less volatile than S&P 500. In comparison Oramed Pharmaceuticals, Inc. has a beta of 1.342, suggesting its more volatile than the S&P 500 by 34.249%.
-
Which is a Better Dividend Stock AVIR or ORMP?
Atea Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals, Inc. offers a yield of 7.58% to investors and pays a quarterly dividend of $0.25 per share. Atea Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oramed Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVIR or ORMP?
Atea Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oramed Pharmaceuticals, Inc. quarterly revenues of --. Atea Pharmaceuticals, Inc.'s net income of -$42M is lower than Oramed Pharmaceuticals, Inc.'s net income of $48.4M. Notably, Atea Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oramed Pharmaceuticals, Inc.'s PE ratio is 3.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atea Pharmaceuticals, Inc. is 0.84x versus 68.69x for Oramed Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVIRAtea Pharmaceuticals, Inc.0.84x -- -- -$42M ORMPOramed Pharmaceuticals, Inc.68.69x 3.29x -- $48.4M
-
Which has Higher Returns AVIR or PMVP?
PMV Pharmaceuticals, Inc. has a net margin of -- compared to Atea Pharmaceuticals, Inc.'s net margin of --. Atea Pharmaceuticals, Inc.'s return on equity of -36.97% beat PMV Pharmaceuticals, Inc.'s return on equity of -51.97%.
Company Gross Margin Earnings Per Share Invested Capital AVIRAtea Pharmaceuticals, Inc.-- -$0.53 $316.8M PMVPPMV Pharmaceuticals, Inc.-- -$0.40 $121.9M -
What do Analysts Say About AVIR or PMVP?
Atea Pharmaceuticals, Inc. has a consensus price target of $7.67, signalling upside risk potential of 66.67%. On the other hand PMV Pharmaceuticals, Inc. has an analysts' consensus of $7.60 which suggests that it could grow by 610.28%. Given that PMV Pharmaceuticals, Inc. has higher upside potential than Atea Pharmaceuticals, Inc., analysts believe PMV Pharmaceuticals, Inc. is more attractive than Atea Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVIRAtea Pharmaceuticals, Inc.2 1 0 PMVPPMV Pharmaceuticals, Inc.6 0 0 -
Is AVIR or PMVP More Risky?
Atea Pharmaceuticals, Inc. has a beta of 0.239, which suggesting that the stock is 76.143% less volatile than S&P 500. In comparison PMV Pharmaceuticals, Inc. has a beta of 1.396, suggesting its more volatile than the S&P 500 by 39.573%.
-
Which is a Better Dividend Stock AVIR or PMVP?
Atea Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PMV Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atea Pharmaceuticals, Inc. pays -- of its earnings as a dividend. PMV Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVIR or PMVP?
Atea Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than PMV Pharmaceuticals, Inc. quarterly revenues of --. Atea Pharmaceuticals, Inc.'s net income of -$42M is lower than PMV Pharmaceuticals, Inc.'s net income of -$21.1M. Notably, Atea Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while PMV Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atea Pharmaceuticals, Inc. is 0.84x versus -- for PMV Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVIRAtea Pharmaceuticals, Inc.0.84x -- -- -$42M PMVPPMV Pharmaceuticals, Inc.-- -- -- -$21.1M
-
Which has Higher Returns AVIR or TIL?
Instil Bio, Inc. has a net margin of -- compared to Atea Pharmaceuticals, Inc.'s net margin of --. Atea Pharmaceuticals, Inc.'s return on equity of -36.97% beat Instil Bio, Inc.'s return on equity of -50.54%.
Company Gross Margin Earnings Per Share Invested Capital AVIRAtea Pharmaceuticals, Inc.-- -$0.53 $316.8M TILInstil Bio, Inc.-- -$2.01 $205.3M -
What do Analysts Say About AVIR or TIL?
Atea Pharmaceuticals, Inc. has a consensus price target of $7.67, signalling upside risk potential of 66.67%. On the other hand Instil Bio, Inc. has an analysts' consensus of $29.00 which suggests that it could grow by 226.58%. Given that Instil Bio, Inc. has higher upside potential than Atea Pharmaceuticals, Inc., analysts believe Instil Bio, Inc. is more attractive than Atea Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVIRAtea Pharmaceuticals, Inc.2 1 0 TILInstil Bio, Inc.1 3 0 -
Is AVIR or TIL More Risky?
Atea Pharmaceuticals, Inc. has a beta of 0.239, which suggesting that the stock is 76.143% less volatile than S&P 500. In comparison Instil Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AVIR or TIL?
Atea Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instil Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atea Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Instil Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVIR or TIL?
Atea Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Instil Bio, Inc. quarterly revenues of --. Atea Pharmaceuticals, Inc.'s net income of -$42M is lower than Instil Bio, Inc.'s net income of -$13.6M. Notably, Atea Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Instil Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atea Pharmaceuticals, Inc. is 0.84x versus -- for Instil Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVIRAtea Pharmaceuticals, Inc.0.84x -- -- -$42M TILInstil Bio, Inc.-- -- -- -$13.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 5.01% over the past day.
Buy
90
TCMD alert for Feb 19
Tactile Systems Technology, Inc. [TCMD] is down 9.98% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 2.56% over the past day.
